SCHEMBL21098148

SCHEMBL21098148

COc1cc(C(C)C)cc2sc(C(C)C)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
NPC1 O15118 1/20 0.34
SCN4A P35499 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP3A4 P08684 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CRHR1 P34998 1/20 0.34
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
PKM P14618 1/20 0.33
TSHR P16473 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20049114 0.84 ACHE (0.37) ALDH1A1CYP3A4TDP1MAPTKMT2A
SCHEMBL21097668 0.84 MAPT (0.48) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL20047427 0.80 ALDH1A1 (0.32) ALDH1A1CYP3A4TDP1MAPTKMT2A
SCHEMBL20049128 0.80 NPC1 (0.41) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL20047500 0.80 CRHR1 (0.32) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL22672569 0.78 CA12 (0.45) PKM
SCHEMBL23502557 0.77 GABRA1 (0.39) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL21160893 0.77 RAB9A (0.36) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL22255014 0.77 ALDH1A1 (0.39) ALDH1A1NPC1SCN4ARAB9ASMN1; SMN2
SCHEMBL13340895 0.75 ALDH1A1 (0.61) ALDH1A1NPC1RAB9ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019118571-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2019-06-20 WO disclosed